Antitumour activity of the HER2 antibody trastuzumab in HER2-overexpressing breast cancers seems to be dependent upon the presence of PTEN, a phosphatase that inhibits phosphatidylinositol 3-kinase-Akt signalling. The gene discussed is ERBB2; the disease is breast carcinoma.